IGF-binding protein-derived peptide or small molecule

Abstract

New compositions based on IGF-binding protein sequences are provided. New tools for high-throughput research are provided. New methods for the treatment of human disease are provided. IGFBP-3-derived peptide or small molecule is administered to subjects having disease, thereby alleviating the symptoms of the disease.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation of U.S. patent application Ser. No. 10 / 383,999, filed Mar. 7, 2003, which is a continuation-in-part of U.S. patent application Ser. No. 10 / 264,672, filed Oct. 4, 2002, which is a continuation-in-part of U.S. patent application Ser. No. 10 / 215,759, filed Aug. 9, 2002, which claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application Ser. No. 60 / 323,267, filed Sep. 18, 2001, all of which are incorporated by reference in their entirety.TECHNICAL FIELD [0002] The invention relates to the compositions and methods of use of peptides or small molecules in the treatment of disease, as well as in high-throughput screening and other discovery and research applications, particularly to the use of metal-binding peptides derived from sequences present in the CD74-homology domain of insulin-like growth factor binding protein-3 (IGFBP-3). BACKGROUND ART [0003] Growth factors are polypeptides which...

AI Technical Summary

Benefits of technology

"The patent text describes the discovery of a protein called IGFBP-3 and the discovery of certain parts of the molecule that have useful properties. These properties include the ability to bind metals like zinc and nickel, and to enter cells and deliver molecules to organs like the heart and kidneys. The text also discusses the use of short peptides called MBD peptides that can mimic the functions of full-length IGFBP-3, but are more stable, potent, and easier to formulate and deliver. The text also mentions that the molecule has a unique structure that allows it to perform various functions and that its activity can be modulated by external factors like iron transport. Overall, the patent text provides a technical solution for using IGFBP-3 and its parts to treat various diseases and disorders."

Problems solved by technology

Most chemotherapeutic agents are effective primarily against dividing cells, and myelosuppression is often the dose-limiting toxicity.

However, to date, IGFBP-3-derived peptides have not been shown to be sufficient for selective, high-affinity binding to any of these ligands.

However, the exact location of this putative protease inhibitor domain has not yet been described.

More recently, a wealth of unpublished data gathered in a number of laboratories fails to support some of the claims made in the above publications.

While there are a large number of cytotoxic drugs available for the treatment of cancer, these drugs are generally associated with a variety of serious side effects, including alopecia, leukopenia, mucositis.

However, to date, IGFBP-3-derived peptides have not been shown to be sufficient for selective, high-affinity binding to any of these ligands.

Reperfusion injury, which occurs upon the reintroduction of blood flow to an ischemic organ, is responsible for considerable damage in heart attacks and strokes.

Images